Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Shadman M, Pasquini M, Ahn KW, Chen Y, et al. Blood 2022;139:1330-1339.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shadman M, Pasquini M, Ahn KW, Chen Y, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood 2022;139:1330-1339.
PMID: 34570879